143 related articles for article (PubMed ID: 33441033)
1. Mnk inhibitors: a patent review.
Abdelaziz AM; Yu M; Wang S
Pharm Pat Anal; 2021 Jan; 10(1):25-35. PubMed ID: 33441033
[TBL] [Abstract][Full Text] [Related]
2. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
[TBL] [Abstract][Full Text] [Related]
5. Progress in developing MNK inhibitors.
Jin X; Yu R; Wang X; Proud CG; Jiang T
Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
9. Update on the Development of MNK Inhibitors as Therapeutic Agents.
Xu W; Kannan S; Verma CS; Nacro K
J Med Chem; 2022 Jan; 65(2):983-1007. PubMed ID: 34533957
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
11. Optimization of 4,6-Disubstituted Pyrido[3,2-
Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
[TBL] [Abstract][Full Text] [Related]
13. Sulfoximine substituted quinazolines for pharmaceutical compositions US 20150005278 (A1): a patent evaluation.
Gopaul K; Koorbanally NA
Expert Opin Ther Pat; 2016 Aug; 26(8):861-9. PubMed ID: 27146589
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
17. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Li P; Basnet SK; Kumarasiri M; Diab S; Teo T; Albrecht H; Wang S
Eur J Med Chem; 2015 May; 95():116-26. PubMed ID: 25800647
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.
Abdelaziz AM; Basnet SKC; Islam S; Li M; Tadesse S; Albrecht H; Gerber C; Yu M; Wang S
Bioorg Med Chem Lett; 2019 Sep; 29(18):2650-2654. PubMed ID: 31362920
[TBL] [Abstract][Full Text] [Related]
20. IL-6 induced upregulation of T-type Ca
Jeevakumar V; Al Sardar AK; Mohamed F; Smithhart CM; Price T; Dussor G
J Neurophysiol; 2020 Jul; 124(1):274-283. PubMed ID: 32519575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]